AzTrials
AzTrials

Bariatric SurgeryBAR-3NCT04861961

Comparison of Three Hypoabsortive Surgical Techniques for Treatment of Type IV Morbid Obesity

A study testing DS vs. SADI-S vs. OAGBP in people with Bariatric Surgery and Morbid Obesity, run by Hospital Universitari de Bellvitge at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Morbid obesity is the first non-traumatic cause of death in the western population and it is also progressively beginning to affect the developing countries. Bariatric surgery provides better results than pharmacological treatments and lifestyle changes, granting a better control of comorbidities. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Bariatric Surgery, Morbid Obesity
What is being tested?
DS vs. SADI-S vs. OAGBP
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
186 participants
Where
1 siteSpain
Study dates
6 Apr 2021to 6 Nov 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients older than 18 and younger than 65 who fulfil bariatric surgery indications
  • BMI between 50 and 60 kg / m2
  • Patients with a good overall condition to perform a one step surgery
  • Signing up of the informed consent for the study
  • Patient suitable for laparoscopic surgery

Who cannot join

  • Previous bariatric surgery
  • Two stage surgery
  • Medical contraindication for a hypoabsorptive surgery due to previous pathology: inflammatory bowel disease, organ transplantation or candidate for a transplant, previous intestinal resection surgery
  • Conversion to laparotomy

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Hospital Universitary de Bellvitge

    L'Hospitalet de Llobregat, Barcelona, 08907

Other trials in Spain

About this study

Official title: Prospective Randomized Study Comparing Three Hypoabsortive Techniques for the Treatment of Type IV Obesity: Double-anastomosis Duodenal Switch (DS), Single- Anastomosis Duodenal Switch SADI-S) and One Anastomosis Gastric By-pass (OAGBP)

Morbid obesity is the first non-traumatic cause of death in the western population and it is also progressively beginning to affect the developing countries. Bariatric surgery provides better results than pharmacological treatments and lifestyle changes, granting a better control of comorbidities.

Duodenal switch (DS) has proben to be the most effective surgical treatment for grade IV morbid obesity and its comorbidities. However, it is not widely used due to its technical complexity and the risk of long-term complications. Single Anastomosis Duodenum-Ileal bypass with Sleeve gastrectomy (SADI-S) was concieved in 2007 as a one-anastomosis simplification of DS, intended to diminish the surgical time and postoperative risks. Recently, another simplified hypo-absorptive technique has started to be widely used: the one anastomosis gastric bypass (OAGBP), also called mini-gastric gypass. It consists of a gastric pouch associated with a gastro-jejunal anastomosis in omega (Billroth II). Despite the potential advantages of these emerging surgical techniques (SADI-S and OAGBP), there is no solid evidence on its efficacy for the treatment of grade IV obesity in comparison with DS. Besides, there is also there is a lack of studies reporting on prospective acid and bile reflux after omega digestive reconstructions, suche as "Billroth II-like" (SADI-S) and "Billroth II" (OAGBP). Bile reflux is potentially premalignant condition.

Read more

This prospective randomized study aims to compare conventional DS with SADI-S and OAGBP. We include all morbidly obese patients with BMI ≥ 50 kg/m2 aged 18 years or more. Exclusion criteria are patients who do not fulfill our preoperative bariatric assessment for surgery and those with contraindications for hypo absorptive or mixed surgery.

The main objective of the study is to compare the percentage of excess weight lost at 2 and 5 years after the three different surgical procedures. As a secondary objective, gastroesophageal reflux (GERD) will be compared before and 2 years after surgery, based on GERD symptoms test, gastroscopy and a esophageal pH-impedanciometry in selected patients. Other secondary objectives are comparison of short-term complications, metabolic comorbidities, depositional habit, quality of life and metabolic and nutritional deficiencies at two years of surgery.

Read the detailed description

Morbid obesity is the first non-traumatic cause of death in the western population and it is also progressively beginning to affect the developing countries. Bariatric surgery provides better results than pharmacological treatments and lifestyle changes, granting a better control of comorbidities.

Duodenal switch (DS) has shown to be the most effective surgical treatment for morbid obesity and its comorbidities. However, it is not widely used due to its technical complexity and the risk of long-term complications. In 2007 Drs. Sánchez-Pernaute and Torres introduced a simplified version of the DS technique: Single Anastomosis Duodenum-Ileal bypass with Sleeve gastrectomy (SADI-S). SADI-S consists of a vertical gastrectomy (VG) and a duodenum-ileal anastomosis preserving the pylorus with jejunal exclusion and a total common-alimentary loop originally of 200 cm and later standardized to 300 cm to reduce the risk of nutritional deficits. In order to diminish the surgical time and postoperative risks an omega reconstruction is performed without an ileo-ileal anastomosis. SADI-S can be performed either directly as primary surgery, planned in two stages, or as revisional surgery in case of insufficient weight loss or weight regain after VG. In terms of weight loss and comorbidity resolution, SADI-S' reported results are similar to those reported in historical DS series, but no prospective comparative studies have been published.

Recently, another simplified hypo-absorptive technique has started to be widely used: the one anastomosis gastric bypass (OAGBP), also called mini-gastric gypass. It consists of a gastric pouch associated with a gastro-jejunal anastomosis (Billroth II). It was initially described by R. Rutledge in 1997 and despite its first publication was in 2001, only lately it has been approved as a standard bariatric technique. OAGBP with a 200 cm biliopancreatic limb has shown good results in weight loss and control of comorbidities, higher than those achieved by VG and proximal Roux-en-Y gastric bypass (RYGBP) with 50 cm biliopancreatic limb and 150 cm alimentary limb, as it has been demonstrated in two prospective randomized studies and a recent meta-analysis. However, the OAGB results have not been compared with other hypo absorptive surgical techniques, such as DS or SADI-S.

In comparison to the DS, which has a Y-Roux reconstruction, SADI-s and OAGBP have a "Billroth II-like" or omega reconstruction. Despite the potential advantages of these emerging surgical techniques, bile reflux is the main issue of omega reconstructions. In our most recently published series including 440 consecutive patients, we reported that 1.7% of patients required conversion to DS due to symptomatic bile reflux. It would be reasonable to expect higher incidence of bile reflux in techniques with omega reconstruction that do not preserve the pyloric barrier, such as OAGBP. However, some authors claim that with a 200 cm biliopancreatic limb most of the bile is reabsorbed by the intestine before it reaches the gastro-jejunal anastomosis. This would minimize bile reflux in comparison to the historical series of Billroth II reconstruction after gastrectomy for oncological or peptic disease (in which the biliopancreatic loop is much shorter, generally around 50 cm). Reported incidences of symptomatic bile reflux after OAGBP vary between 0.5% and 1.5%, comparable to our SAID-S results. It is worth mentioning that not all bile refluxes are symptomatic and that biliary gastritis is a premalignant condition. At present, there is a lack of literature on acid and bile reflux after bariatric surgery comparing the 3 digestive reconstruction techniques: (i) Roux-en-Y with pyloric preservation (DS), (ii) omega reconstruction with pyloric preservation or "Billroth II-like" (SADI-S) and (iii) omega reconstruction without pyloric preservations or Billroth II (OAGBP).

This prospective randomized study aims to compare conventional DS with SADI-S and OAGBP. We include all morbidly obese patients with BMI ≥ 50 kg/m2 and candidates to a directly DS following our treatment algorithm. Exclusion criteria are patients who do not fulfill our preoperative bariatric assessment for surgery and those with contraindications for hypo absorptive or mixed surgery.

The main objective of the investigation is to compare the percentage of excess weight lost at 2 and 5 years after the three different surgical procedures. For the study of weight evolution, both Dietetics' and General Surgery's postoperative standardized routine controls at our outpatient centre will be used.

As a secondary objective, gastroesophageal reflux (GER) will be compared before and 2 years after surgery. A GER's symptoms test, gastroscopy and a esophageal pH-impedance analysis in selected patients will be employed. Other secondary objectives include the comparison of short-term complications, metabolic comorbidities, bowel habit and quality of life two years after the surgical procedure. Furthermore, a medium and long term follow up on metabolic and nutritional deficiency will be performed.

For the morbidity and mortality analysis, the patients' electronic medical history records will be revised. Short postoperative complications (up to 30th postoperative day) will be classified according to Clavien-Dindo classification. Comorbidities' evolution will be evaluated following our centre follow-up protocol before and annually after the surgery. Data will be collected in a prospective database. The quality-of-life study will be carried out with the SF-12 test. The metabolic and nutritional deficit analysis will be carried out through the annual analytical data collected during the follow-up of the patients according to common clinical practice.

Being tested
DS vs. SADI-S vs. OAGBP
Keywords
Bariatric Surgery, Morbid Obesity, Hypoabsortive surgery, Duodenal Switch, SADI-S, One-anastomosis gastric by-pass, Gastro-esophageal reflux
Medical subject headings
Obesity, Morbid, Gastroesophageal Reflux

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DS vs. SADI-S vs. OAGBPProcedure or surgery

    Randomizacion of candidates for either conventional DS, SADI-S or OAGBP.

Study groups in NCT04861961
Study groupRoleWhat they receive
Laparoscopic duodenal switch (DS)Active comparatorStandard duodenal switch (double anastomoses). Roux-en-Y reconstruction.
Receives: Procedure: DS vs. SADI-S vs. OAGBP
Laparoscopic Single Anastomosis Duodenum-Ileal bypass with Sleeve gastrectomy (SADI-S)Active comparatorSimplified duodenal switch with one anastomosis. Duodeno-ileal omega reconstruction ("Billroth II-like").
Receives: Procedure: DS vs. SADI-S vs. OAGBP
Laparoscopic one anastomosis gastric bypass (OAGBP)Active comparatorGastric bypass of one anastomoses. Gastro-jejunal omega reconstruction (Billroth II).
Receives: Procedure: DS vs. SADI-S vs. OAGBP

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of excess weight lost (% EWL)

    % EWL considering ideal BMI = 25 kg/m2

    Measured: At 5 years after surgery

Secondary outcomes (7)
  1. Gastroesophageal reflux

    Gastroesophageal reflux as defined by the Lyon Consensus

    Measured: 2 years after surgery

  2. Postoperative complications

    Complications will be recorded according to the Clavien-Dindo classification

    Measured: 30 days after surgery

  3. Postoperative mortality

    Short-term mortality after surgery

    Measured: 90 days after surgery

  4. Metabolic comorbidities

    Comorbidities related to metabolic syndrome and morbid obesity: Type-2 diabetes (DM2), arterial hypertension (HT), dyslipidemia (DLP) and obstructive sleep apnea (OSA).

    Measured: At 5 years of surgery

  5. Quality of life (SF-12 test)

    Quality of life determined by the SF-12 test

    Measured: At 2 years of surgery

  6. Depositional habit

    The number of depositions per day, the consistency of the depositions according to the Bristol visual scale and faecal incontinence and / or defecation urgency according to Wexner Vaixey scale

    Measured: At 2 years of surgery

  7. Need of revisional surgery

    Revisonal surgery due to nutritional defficiencie, gastroesophageal reflux or other causes

    Measured: At 5 years of surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Apr 2021
  2. Study start6 Apr 2021
  3. Primary completion6 Nov 2023
  4. Study completion6 Nov 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Prospective randomized study comparing three bariatric surgical techniques
Masking
Single blind
Who is masked
Participant
Enrolment
186 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04861961
Sponsor's protocol ID
BAR-3
Acronym
BAR-3
Status last verified
Dec 2023
First submitted
22 Apr 2021
Last updated
29 Dec 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: On demand to IP

Publications

  • Finno P, Osorio J, Garcia-Ruiz-de-Gordejuela A, Casajoana A, Sorribas M, Admella V, Serrano M, Marchesini JB, Ramos AC, Pujol-Gebelli J. Single Versus Double-Anastomosis Duodenal Switch: Single-Site Comparative Cohort Study in 440 Consecutive Patients. Obes Surg. 2020 Sep;30(9):3309-3316. doi: 10.1007/s11695-020-04566-5.

    PubMed 32240495
  • Sorribas M, Casajoana A, Sobrino L, Admella V, Osorio J, Pujol-Gebelli J. Experience in biliopancreatic diversion with duodenal switch: results at 2, 5 and 10 years. Cir Esp (Engl Ed). 2021 Feb 13:S0009-739X(21)00030-0. doi: 10.1016/j.ciresp.2021.01.008. Online ahead of print. English, Spanish.

    PubMed 33593597
  • Admella V, Osorio J, Sorribas M, Sobrino L, Casajoana A, Pujol-Gebelli J. Direct and two-step single anastomosis duodenal switch (SADI-S): Unicentric comparative analysis of 232 cases. Cir Esp (Engl Ed). 2021 Aug-Sep;99(7):514-520. doi: 10.1016/j.cireng.2021.06.017. Epub 2021 Jul 1.

    PubMed 34217637

Questions about this trial

What is this clinical trial studying?

A study testing DS vs. SADI-S vs. OAGBP in people with Bariatric Surgery and Morbid Obesity, run by Hospital Universitari de Bellvitge at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of excess weight lost (% EWL) (time frame: At 5 years after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04861961, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Dec 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in